Moleculin Stock Today

MBRX -  USA Stock  

USD 1.51  0.07  4.86%

Market Performance
0 of 100
Odds Of Distress
Less than 47
Moleculin Biotech is trading at 1.51 as of the 27th of May 2022; that is 4.86 percent increase since the beginning of the trading day. The stock's open price was 1.44. Moleculin Biotech has 47 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Moleculin Biotech CS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of June 2020 and ending today, the 27th of May 2022. Click here to learn more.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. The company has 28.58 M outstanding shares of which 301.02 K shares are now shorted by private and institutional investors with about 2.87 trading days to cover. More on Moleculin Biotech CS

Moleculin Biotech Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Moleculin Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Moleculin Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Moleculin Biotech generated a negative expected return over the last 90 days
Moleculin Biotech may become a speculative penny stock
Moleculin Biotech has high historical volatility and very poor performance
Net Loss for the year was (15.89 M) with profit before overhead, payroll, taxes, and interest of 0.
Moleculin Biotech CS currently holds about 70.9 M in cash with (18.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Moleculin Biotech has a very weak financial position based on the latest SEC disclosures
Moleculin Biotech Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Moleculin Biotech SEC Filings
Moleculin Biotech SEC Filings Security & Exchange Commission EDGAR Reports
New SymbolMBRX1
Thematic Classification
Currently Active Investing Idea (view all)
Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Moleculin Biotech report their recommendations after researching Moleculin Biotech's financial statements, talking to executives and customers, or listening in on Moleculin Biotech's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Moleculin Biotech. The Moleculin consensus assessment is calculated by taking the average forecast from all of the analysts covering Moleculin Biotech.
Strong Buy3 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Moleculin Biotech based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Moleculin Biotech financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 1 - Very WeakDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares29 M26.9 M
Significantly Up
Slightly volatile
Weighted Average Shares Diluted29 M26.9 M
Significantly Up
Slightly volatile
Total Assets90.7 M84.1 M
Significantly Up
Slightly volatile
Total Liabilities5.5 M5.1 M
Significantly Up
Slightly volatile
Current Assets78.2 M72.5 M
Significantly Up
Slightly volatile
Current Liabilities3.3 M3.6 M
Significantly Down
Slightly volatile
Total Debt64.7 K63 K
Fairly Up
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Moleculin Biotech's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Moleculin Biotech's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Moleculin Biotech's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Moleculin Biotech's financial leverage. It provides some insight into what part of Moleculin Biotech's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Moleculin Biotech's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Moleculin Biotech deploys its capital and how much of that capital is borrowed.
Moleculin Biotech cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 159 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Moleculin Biotech has a current ratio of 19.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Moleculin Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Moleculin Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Moleculin Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Moleculin to invest in growth at high rates of return. When we think about Moleculin Biotech's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(19.45 Million)Share
Moleculin Biotech CS (MBRX) is traded on NASDAQ Exchange in USA. It is located in 5300 Memorial Drive and employs 13 people. Moleculin Biotech is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 37.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Moleculin Biotech's market, we take the total number of its shares issued and multiply it by Moleculin Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Moleculin Biotech conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 28.58 M outstanding shares of which 301.02 K shares are now shorted by private and institutional investors with about 2.87 trading days to cover. Moleculin Biotech CS currently holds about 70.9 M in cash with (18.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Moleculin Biotech Probability Of Bankruptcy
Moleculin Biotech maintains a total of twenty-eight million five hundred eighty thousand outstanding shares. Roughly 83.0 % of Moleculin Biotech outstanding shares are held by regular investors with 2.15 pct. owned by insiders and only 14.67 % by institutional investors. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Moleculin Ownership Details

Moleculin Stock Price Odds Analysis

What are Moleculin Biotech's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Moleculin Biotech jumping above the current price in 90 days from now is about 91.15%. The Moleculin Biotech CS probability density function shows the probability of Moleculin Biotech stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Moleculin Biotech has a beta of 0.7787. This indicates as returns on the market go up, Moleculin Biotech average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Moleculin Biotech CS will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Moleculin Biotech is significantly underperforming DOW.
  Odds Below 1.51HorizonTargetOdds Above 1.51
8.82%90 days
Based on a normal probability distribution, the odds of Moleculin Biotech to move above the current price in 90 days from now is about 91.15 (This Moleculin Biotech CS probability density function shows the probability of Moleculin Stock to fall within a particular range of prices over 90 days) .

Moleculin Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Moleculin Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Moleculin Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Moleculin Biotech's value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares1.1 M1.9 M
Sio Capital Management LlcCommon SharesM1.9 M
View Moleculin Biotech Diagnostics

Moleculin Biotech Historical Income Statement

Moleculin Biotech CS Income Statement is one of the three primary financial statements used for reporting Moleculin's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Moleculin Biotech revenue and expense. Moleculin Biotech Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Moleculin Biotech Interest Expense is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Interest Expense of 38,700 in 2021. Weighted Average Shares is likely to rise to about 29 M in 2022, whereas Consolidated Income is likely to drop (16.3 M) in 2022. View More Fundamentals

Moleculin Stock Against Markets

Picking the right benchmark for Moleculin Biotech stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Moleculin Biotech stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Moleculin Biotech is critical whether you are bullish or bearish towards Moleculin Biotech CS at a given time.

Similar Equity Warning - MBRX

Moleculin Biotech was forked

The entity Moleculin Biotech CS with a symbol MBRX was recently forked. You can potentially use METABASIS THERAPEUTICS INC with a symbol MBRX1 from now on.

Investing Moleculin Biotech CS

You need to understand the risk of investing before taking a position in Moleculin Biotech. The danger of trading Moleculin Biotech CS is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Moleculin Biotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Moleculin Biotech. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Moleculin Biotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Fundamental Analysis
View fundamental data based on most recent published financial statements
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Bond Directory
Find actively traded corporate debentures issued by US companies
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.